Amoxapine-induced tardive dyskinesia.
A case report of amoxapine-induced tardive dyskinesia following discontinuation of amoxapine therapy is reported. During 68 weeks of therapy, the patient received a maximum of amoxapine 400 mg/d. Six months after amoxapine discontinuation, the patient continued to have symptoms of tardive dyskinesia. These symptoms correlate with the dopamine receptor-blocking property of amoxapine and its metabolites. We propose that amoxapine therapy be monitored for the long-term as well as the short-term adverse effects of dopamine receptor-blockade.
D000368:Aged; D000657:Amoxapine / Q000009:adverse effects*; D003989:Dibenzoxazepines / Q000009:adverse effects*; D004409:Dyskinesia, Drug-Induced / Q000209:etiology*; D006801:Humans; D008297:Male; D013375:Substance Withdrawal Syndrome / Q000209:etiology*
D003989:Dibenzoxazepines; D000657:Amoxapine